Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

23.10EUR
4:52am EST
Change (% chg)

€-0.10 (-0.43%)
Prev Close
€23.20
Open
€23.20
Day's High
€23.35
Day's Low
€23.00
Volume
2,214
Avg. Vol
7,543
52-wk High
€29.50
52-wk Low
€19.50

Latest Key Developments (Source: Significant Developments)

Carmat Appoints Jean-Pierre Garnier As New Chairman Of The Board Of Directors
Monday, 3 Dec 2018 12:00pm EST 

Dec 3 (Reuters) - CARMAT SA ::ANNOUNCES THE APPOINTMENT OF JEAN-PIERRE GARNIER AS CHAIRMAN OF THE BOARD OF DIRECTORS.COOPTATION OF JEAN-PIERRE GARNIER TO COMPANY'S BOARD OF DIRECTORS, REPLACING FORMER CHAIRMAN, JEAN-CLAUDE CADUDAL, WHO STOOD DOWN.  Full Article

Carmat Says To Keep Patient Enrollment Pace In Line With Its Goal To Finalize Pivotal Study By Year-End
Tuesday, 20 Feb 2018 11:58am EST 

Feb 20 (Reuters) - Carmat ::SAYS ADVANCES THE INTERNATIONALIZATION OF THE PIVOTAL STUDY AND OBTAINS THE APPROVAL TO PERFORM IMPLANTS IN DENMARK‍​.HEART CENTER OF THE RIGSHOSPITALET HOSPITAL IN COPENHAGEN SAYS TO EVALUATE THE CARMAT ARTIFICIAL HEART FOR THE TREATMENT OF END-STAGE HEART-FAILURE PATIENTS.SAYS EXPECT TO PURSUE STRATEGY OF CREATING A POOL OF HIGHLY SPECIALIZED CENTERS, TO INCLUDE THREE MORE CENTERS IN THE UPCOMING MONTHS.SAYS THIS SHOULD ALLOW TO SUSTAIN THE PATIENT ENROLLMENT PACE IN LINE WITH ITS OBJECTIVE OF FINALIZING THE PIVOTAL STUDY BY THE END OF THIS YEAR.  Full Article

Carmat Launches Capital Increase For Initial Amount Of 46 Million Euros
Tuesday, 5 Dec 2017 01:01am EST 

Dec 5 (Reuters) - Carmat ::LAUNCHES A CAPITAL INCREASE WITHOUT SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS AND WITH A 4-TRADING DAY PRIORITY SUBSCRIPTION PERIOD ON AN IRREDUCIBLE BASIS TO SHAREHOLDERS FOR AN INITIAL AMOUNT OF €46 MILLION.LAUNCHES A CAPITAL INCREASE WITHOUT SHAREHOLDERS’ PREFERENTIAL SUBSCRIPTION RIGHTS AND WITH A 4-TRADING DAY PRIORITY SUBSCRIPTION PERIOD ON AN IRREDUCIBLE BASIS TO SHAREHOLDERS FOR AN INITIAL AMOUNT OF €46 MILLION.‍LAUNCH OF CAPITAL INCREASE WITHOUT SHAREHOLDERS' PREFERENTIAL SUBSCRIPTION RIGHTS FOR AMOUNT OF EUR 46 MILLION​.‍INITIAL AMOUNT MAY BE INCREASED TO MAX OF EUR 52.9 MILLION IN EVENT OF FULL EXERCISE OF INCREASE OPTION​.‍CAPITAL INCREASE TO SECURE FINAL DEVELOPMENT STAGES BEFORE MARKETING OF TOTAL ARTIFICIAL HEART IN EUROPE​.‍MARKETING OF TOTAL ARTIFICIAL HEART IN EUROPE SCHEDULED FOR 2019​.‍EXISTING SHAREHOLDERS ALREADY COMMITTED TO SUBSCRIBE FOR AMOUNT OF EUR 34.5M​.‍MAX NUMBER OF NEW SHARES THAT MAY BE ISSUED IS 4.0 MILLION.‍BNP PARIBAS AND ODDO BHF SCA ACTING AS GLOBAL COORDINATORS, LEAD MANAGERS AND JOINT-BOOKRUNNERS​.‍PORTZAMPARC IS ACTING AS CO-LEAD MANAGER​.‍MAX SUBSCRIPTION PRICE OF NEW SHARES WILL BE EUR 20 PER SHARE​.  Full Article

Carmat: First Implantation In Czech Republic Within Framework Of Pivotal Study International Expansion
Monday, 27 Nov 2017 12:01pm EST 

Nov 27 (Reuters) - CARMAT ::FIRST IMPLANTATION IN THE CZECH REPUBLIC WITHIN THE FRAMEWORK OF THE PIVOTAL STUDY INTERNATIONAL EXPANSION.‍COMPLETION EXPECTED BY END OF 2018​.  Full Article

Carmat signs a partnership agreement with AddUp
Monday, 13 Nov 2017 01:01am EST 

Nov 13 (Reuters) - CARMAT : :CARMAT SIGNS A PARTNERSHIP AGREEMENT WITH ADDUP, THE MICHELIN AND FIVES JOINT VENTURE SPECIALIZED IN 3D PRINTING.‍AIM OF COLLABORATION IS TO STRENGTHEN INDUSTRIAL DEVELOPMENT OF CARMAT HEART AND CONTRIBUTE TO INCREASE CO'S PRODUCTION CAPACITY IN PREPARATION FOR LARGE SCALE PRODUCTION PHASE​.  Full Article

French group Carmat says gets approval to perform implants in Czech Republic
Monday, 30 Oct 2017 02:00am EDT 

Oct 30 (Reuters) - Carmat Sa ::* Received the approval to perform, within the framework of the PIVOTAL study protocol approved by the ANSM (French national agency for the safety of medicines and health products), implants of its total artificial heart in patients at the Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.  Full Article

Carmat reports H1 operating expenses of 14.7 million euros
Tuesday, 26 Sep 2017 12:01pm EDT 

Sept 26 (Reuters) - CARMAT ::‍CASH POSITION OF EUR 19.9 MILLION AT JUNE 30, 2017​.‍CONFIRMATION OF OBJECTIVE OF COMPLETING PIVOTAL STUDY AT END OF 2018​.OPERATING EXPENSES IN LINE WITH THE ACCELERATION OF THE COMPANY’S INDUSTRIAL DEVELOPMENT.H1 TOTAL OPERATING INCOME EUR 7,000 VERSUS EUR 96,827 YEAR AGO.H1 NET LOSS EUR 14.1 MILLION VERSUS LOSS OF EUR 10.2 MILLION YEAR AGO.‍CARMAT RECORDED NO REVENUE OVER FIRST HALF OF 2017​.‍FINANCIAL RESOURCES WILL ENABLE COMPANY TO CONTINUE ITS INDUSTRIAL AND CLINICAL DEVELOPMENT UNTIL BEGINNING OF Q2 OF 2018​.  Full Article

French and Benelux stocks-Factors to watch on August 2

Aug 2 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.